Biological distribution of 131I-HAb18F(ab')2 in patients with hepatocellular carcinoma / 生物医学工程学杂志
Journal of Biomedical Engineering
; (6): 689-691, 2003.
Article
in Zh
| WPRIM
| ID: wpr-312895
Responsible library:
WPRO
ABSTRACT
Before 131I-HAb18F(ab')2 administration, 24 cases of mid-term or advanced hepatocellular carcinoma(HCC) were given Lugol's Liquid to block the thyroid gland, and submitted to hepatic colloid imaging. The cases were randomly divided into 3 groups. Then 131I-HAb18F(ab')2 was injected into the target hepatic artery with doses of 0.5, 0.75, 1.0 mCi/kg, respectively. At the followed 10, 48, 96 and 192 hours, 131I-HAb18F(ab')2 distribution in human body was acquired by whole body dynamic image with Single photon emission computed tomography(SPECT). The results showsed that 131I-HAb18F(ab')2 in tumor tissue was significantly higher than that in normal liver tissue and other organs. This difference became obvious as time passed. 131I-HAb18F(ab')2 is stable in human body and it can combine with HCC tissue specifically. So it is a new medicine deserving further research for the treatment of HCC.
Full text:
1
Index:
WPRIM
Main subject:
Radiotherapy
/
Immunoglobulin Fab Fragments
/
Pharmacokinetics
/
Tissue Distribution
/
Radioimmunotherapy
/
Carcinoma, Hepatocellular
/
Radiopharmaceuticals
/
Iodine Radioisotopes
/
Liver Neoplasms
/
Metabolism
Limits:
Adult
/
Aged
/
Female
/
Humans
/
Male
Language:
Zh
Journal:
Journal of Biomedical Engineering
Year:
2003
Type:
Article